BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed EXEL catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:8169a31d9faa6ec911d7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:EXEL P3 readout (est.): STELLAR-304
DESCRIPTION:Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanc
 ed or Metastatic Non-Clear Cell Renal Cell Carcinoma\nNCT05678673 | PHASE3
  | ACTIVE_NOT_RECRUITING | sponsor: Exelixis\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker EXEL (confidence 
 0.9)\nSource: https://clinicaltrials.gov/study/NCT05678673\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05678673
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
